Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM phase II trial of alternative ipilimumab + nivolumab schedules in advanced renal cell carcinoma
ISRCTN95351638Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in renal cell carcinoma (RCC) (2 arms), sponsored by University of Leeds. Started Jan 2018; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ISRCTN95351638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95351638.